Related Experiment Videos
Long-term complete remission in IgD-myeloma.
R H H Bemelmans1, D W van Toorn, L van Leeuwen
1Department of Internal Medicine, Gelre Hospitals, Apeldoorn, The Netherlands.
European Journal of Haematology
|March 8, 2006
Summary
Long-term complete remission is rare in IgD multiple myeloma (MM). This case report details a patient achieving a sustained cure after conventional chemotherapy, despite adverse prognostic factors, highlighting a potential treatment success for this rare cancer.
Area of Science:
- Hematology
- Oncology
- Clinical Case Studies
Background:
- IgD multiple myeloma (MM) is a rare subtype of plasma cell disorder.
- Complete and long-term remission in IgD-MM is exceptionally uncommon.
- Conventional chemotherapy regimens are often less effective in IgD-MM compared to other myeloma types.
Observation:
- A patient diagnosed with stage IIIB IgD-MM was treated with standard melphalan and prednisone chemotherapy.
- The patient achieved complete disappearance of monoclonal protein after four cycles of treatment.
- Therapy was completed after 14 cycles, with a subsequent follow-up period exceeding 8 years.
Findings:
- The patient has maintained a complete remission for over 8 years post-treatment.
- This sustained remission suggests a potential cure for IgD-MM, even with adverse prognostic factors.
- The case demonstrates the efficacy of conventional chemotherapy in achieving long-term outcomes for a rare myeloma variant.
Implications:
- This case provides a rare example of a potential cure for IgD multiple myeloma.
- It suggests that conventional chemotherapy may be effective in select IgD-MM patients.
- Further research into IgD-MM treatment strategies is warranted, given its rarity and poor prognosis.